The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of Metabolism

NCT01780168 | Recruiting

• 2 other identifiers: 13005313-HG-0053
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

The Metabolism, Infection and Immunity (MINI) Study is a longitudinal natural history study at the National Institutes of Health (NIH) that aims to define the relationship between infection, immunity and clinical decline in individuals with mitochondrial disease. Mitochondrial diseases are a group of disorders caused by problems with the cell s ability to produce energy. Infection in individuals with mitochondrial disease can lead to worsening clinical symptoms, particularly neurologic symptoms. Goals: The main goal of our study is to understand the relationship between infection and clinical decline in patients with mitochondrial disease. Mitochondrial diseases can affect many different parts of the body, including the immune system and its ability to respond to infection. Therefore, we perform a comprehensive evaluation of participants including a detailed immunologic assessment. We are not testing any new medicine or procedure to treat or cure IEM or mitochondrial diseases. However, by understanding the relationship between infection and mitochondrial disease, we hope to develop treatments in the future. At the NIH, we are interested in research. Although we do provide advice and care for people enrolled in our study, we are not able to take over the long-term care of participants. To enroll in our study, you (your child) must already have a confirmed diagnosis of a mitochondrial disease. We are not able to provide a "first time" diagnosis or regular metabolic care. What is involved? Once you contact our team members, you will be asked to provide medical records to determine eligibility. Our team will review the records and notify you if you (your child is) eligible to join the study.

• Onsite participation: You (your child) will be invited to visit the National Institutes of Health in Bethesda, Maryland. This first visit will typically last 3-5 days. Depending on the level of participation, additional visits may be requested. Our team members will work with you and your child to coordinate the supports needed during your stay at NIH. Study participants may be seen in the clinic, day hospital or inpatient setting. When you (your child) arrive at the NIH we will have an informed consent discussion to confirm willingness to participate, answer questions and review the risks and benefits of the study. You (your child) will meet with a physician who will ask about medical and family history and do a physical exam (like in any doctor's office). We will ask all study participants to allow us to collect urine, draw blood, swab your (your child s) nose, and perform a detailed assessment. We may suggest additional evaluations or specialty consults for some participants based on clinical manifestations, age and level of independence. We will explain these studies to you (your child). They may include items such as- imaging studies, DEXA or MRI scan, energy expenditure or metabolic testing, developmental neuropsychological logical testing, physiatry, ophthalmology, or other consults. In some cases, we may request a skin biopsy (if one has not been done). You will receive the results of your (your child's) clinical testing and notes from any clinical consultations.
• Remote participation: If you (your child) are unable to travel, you (your child) may be enrolled remotely for records review, questionnaires, and telethealth exams. Blood or other samples collection may be requested in coordination with local providers or lab testing companies...

Conditions

Oxidative Phosphorylation Deficiencies; Electron Transport Chain Disorders, Mitochondrial; Mitochondrial Disorders; Leigh Disease

Keywords

Mitochondrial Disorders; Leigh Disease; Subacute Necrotizing Encephalopathy; Disorders of Oxidative Phosphorylation (OXPHOS); Natural History

Outcome Measures

Primary Outcomes (2)

• To provide insight into the mechanisms involved in the interplay between the immune system and mitochondrial metabolism

  By developing an understanding of immune dysfunction, targets for rational therapies may be developed for this patient population.

  Initial visit and various timepoints thereafter dependent on protocol

• To document the development of adaptive immunity in cohorts of mitochondrial disease patients according to the standard of care for this vulnerable population.

  By developing an understanding of immune dysfunction, targets for rational therapies may be developed for this patient population.

  Initial visit and various timepoints thereafter dependent on protocol

Study Arms (2)

healthy volunteers

Healthy volunteers

Inborn errors of metabolism/mitochondrial disease

patients with inborn errors of metabolism including those with mitochondrial disease

Eligibility Criteria

• Age: 2 Years - 115 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with inborn errors of metabolism including those with mitochondrial disease

You may qualify if:

• In order to be eligible to paraticipant in this study, an individual must meet all of the following criteria:
• Stated willingness to comply with all study procedures and availability for the duration of the study.
• Male or female, \>12 months of age.
• Diagnosis of mitochondrial disease with documented molecular evidence of disease.
• Healthy volunteers of any gender and ethnicity \>2 years of age may also be eligible to enroll in the protocol. Healthy volunteers may be from the local community, or family members of patients with MtD.
• Agreement to adhere to Lifestyle considerations throughout study duration.
• Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.

You may not qualify if:

• Lack of a local MtD provider (For participants with MtD only)
• \<12 months of age
• Pregnancy or lactation
• Discretion and clinical judgement of the Principal Investigator

Sponsors & Collaborators

• National Human Genome Research Institute (NHGRI): lead

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

RECRUITING

Related Publications (1)

• Kruk SK, Pacheco SE, Koenig MK, Bergerson JRE, Gordon-Lipkin E, McGuire PJ. Vulnerability of pediatric patients with mitochondrial disease to vaccine-preventable diseases. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2415-2418.e3. doi: 10.1016/j.jaip.2019.03.046. Epub 2019 Apr 5. No abstract available.

  PMID: 30954647 BACKGROUND

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Conditions

Mitochondrial Diseases; Leigh Disease

Condition Hierarchy (Ancestors)

Metabolic Diseases; Nutritional and Metabolic Diseases; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Pyruvate Metabolism, Inborn Errors; Carbohydrate Metabolism, Inborn Errors

Study Officials

• Peter J McGuire, M.D.

  National Human Genome Research Institute (NHGRI)

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Shannon K Kruk, R.N.

CONTACT

(301) 451-9145; shannon.kruk@nih.gov

Peter J McGuire, M.D.

CONTACT

(301) 451-7716; peter.mcguire@nih.gov

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 29, 2013
• First Posted: January 30, 2013
• Study Start: December 31, 2012
• Primary Completion (Estimated): December 31, 2026
• Last Updated: May 5, 2026

Record last verified: 2026-01-14

Locations

US (1)